• Rapid Micro Biosystems priced an underwritten follow-on offering of 3,581,000 Class A shares with Series A and Series B warrants, alongside up to 1,463,000 pre-funded warrants with the same warrant coverage.
• Each share and accompanying warrants were priced at USD 1.96; each pre-funded warrant and accompanying warrants at USD 1.95.
• Gross proceeds are expected to be about USD 9.8 million, with up to an additional USD 21.7 million if the pre-funded warrants and all Series A and Series B warrants are exercised for cash.
• Bain Capital Life Sciences, Armistice Capital, and certain directors and officers are participating, including a concurrent registered direct sale of 71,607 shares with accompanying Series A and Series B warrants.
• Series A warrants carry a USD 1.96 exercise price, become exercisable in six months, and expire after one year; Series B warrants carry a USD 2.34 exercise price, become exercisable in six months, and expire after five years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapid Micro Biosystems Inc. published the original content used to generate this news brief on May 18, 2026, and is solely responsible for the information contained therein.